Hormone replacement therapy in young women with surgical primary ovarian insufficiency

Fertility and Sterility

Volumn 106, Issue 7, 2016, Pages 1580-1587

  Sarrel, Philip M ^a   Sullivan, Shannon D ^b   Nelson, Lawrence M ^c  

^a YALE UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

estrogen therapy; ovarian insufficiency; Premenopausal oophorectomy; surgical menopause

Indexed keywords

ESTRADIOL;

BREAST CANCER; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MENOPAUSE; MOOD DISORDER; MORBIDITY; MORTALITY; OSTEOPOROSIS; OVARIECTOMY; OVARY INSUFFICIENCY; PREMENOPAUSE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYMPTOMATOLOGY; TREATMENT PLANNING; ADVERSE EFFECTS; AGE; FEMALE; PATHOPHYSIOLOGY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OVARIECTOMY; PRIMARY OVARIAN INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84998611061     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2016.09.018     Document Type: Review

References (76)

1. 1 Asante, A., Whiteman, M.K., Kulkarni, A., Cox, S., Marchbanks, P.A., Jamieson, D.J., Elective oophorectomy in the United States: trends and in-hospital complications, 1998–2006. Obstet Gynecol 116 (2010), 1088–1095.
2. 2 Wright, J.D., Herzog, T.J., Tsui, J., Ananth, C.V., Lewin, S.N., Lu, Y.S., et al. Nationwide trends in the performance of hysterectomy in the United States. Obstet Gynecol 122 (2013), 233–241.
3. 3 Rebbeck, T.R., Kauff, N.D., Domcheck, S.M., Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 191 (2009), 80–87.
4. 4 Gierach, G.L., Pfeiffer, R.M., Patel, D.A., Black, A., Schairer, C., Gill, A., et al. Long-term overall and disease-specific, mortality associated with benign gynecologic surgery performed at different ages. Menopause 21 (2014), 592–601.
5. 5 Shuster, L.T., Rhodes, D.J., Gostout, B.S., Grosshardt, B.R., Rocca, W.A., Premature menopause or early menopause: long-term health consequences. Maturitas 65 (2010), 161–166.
6. 6 Faubion, S.S., Kuhle, C.L., Shuster, L.T., Rocca, W.A., Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18 (2015), 483–491.
7. 7 Rossouw, J.E., Prentice, R.L., Manson, J.E., Wu, L., Barad, D., Barnabei, V.M., et al. Postmenopausal hormone therapy and the risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007), 1465–1477.
8. 8 Chubaty, A., Shandro, M.T., Schuurmans, N., Yuksel, N., Practice patterns with hormone therapy after surgical menopause. Maturitas 69 (2011), 69–73.
9. 9 Benshushan, A., Rojansky, N., Chaviv, M., Arbel-Alon, S., Benmeir, A., Imbar, T., et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 12 (2009), 404–409.
10. 10 Nachtigall, L., Hot flashes: is a hot flash just a hot flash?. Menopause 21 (2014), 1–2.
11. 11 Thurston, R.C., El Khoudary, S.R., Sutton-Tyrrell, K., Crandall, C.J., Gold, E., Sternfeld, B., et al. Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women's Health Across the Nation. Menopause 18 (2011), 1044–1051.
12. 12 Kronenberg, F., Hot flashes, epidemiology and physiology. Ann N Y Acad Sci 592 (1990), 122–133.
13. 13 Challberg, J., Ashcroft, L., Lalloo, F., Eckersley, B., Clayton, R., Hopwood, P., et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105 (2011), 22–27.
14. 14 Freedman, R.R., Physiology of hot flashes. Am J Hum Biol 13 (2001), 453–464.
15. 15 Sarrel, P.M., Lindsay, D.C., Rosano, G.M.C., Poole-Wilson, P.A., Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol 167 (1992), 467–472.
16. 16 Sarrel, P.M., Sexuality and menopause. Obstet Gynecol 75:Suppl (1990), 26S–30S.
17. 17 Thurston, R.C., Aizenstein, H.J., Derby, C.A., Sejdic, E., Maki, P.M., Menopausal hot flashes and white matter hyperintensities. Menopause 23 (2016), 27–31.
18. 18 Bove, R., Secor, E., Chibnik, L.B., Barnes, L.L., Schneider, J.A., Bennett, D.A., et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 82 (2014), 222–229.
19. 19 Sarrel, P.M., Portman, D., Lefebvre, M.A., Lafeuille, M.H., Grittner, A.M., Fortier, J., et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause 22 (2015), 260–266.
20. 20 Geukes, M., van Aalst, M.P., Rebroek, S.J.W., Laven, J.S.E., Oosterhof, H., The impact of menopause on work ability in women with severe menopausal symptoms. Maturitas 90 (2016), 3–8.
21. 21 Graziottin, A., Basson, R., Sexual dysfunction in women with premature menopause. Menopause 11 (2004), 766–777.
22. 22 Shifren, J.L., Braunstein, G.D., Simon, J.A., Casson, P.R., Buster, J.E., Redmond, G.P., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343 (2000), 682–688.
23. 23 Tucker, P.E., Bulsara, M.K., Salfinger, S.G., Tan, J.J., Green, H., Cohen, P.A., The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy. Maturitas 85 (2016), 42–48.
24. 24 Rosenberg, L., Hennekens, C.H., Rosner, B., Belanger, C., Rothman, K.J., Speizer, F.E., Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139 (1981), 47–51.
25. 25 Thurston, R.C., Barinas-Mitchell, E., Jennings, J.R., Santoro, N., von Kanel, R., Chang, Y., et al. Physiologically monitored hot flashes and subclinical cardiovascular disease among midlife women. Menopause, 22, 2015, 1371.
26. 26 Kerber, I.J., Turner, R.J., Eu-estrogenemia, KNDY neurons, and vasomotor symptoms. JAMA Intern Med, 175, 2015, 1586.
27. 27 Hodis, H.N., Mack, W.J., The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Parts 1 and 2. J Am Geriatr Soc 61 (2013), 1005–1018.
28. 28 Hodis, H.N., Mack, W.J., Henderson, V.W., Kono, N., Stanczyk, F., Selzer, S., et al. Vascular effects of early vs late postmenopausal treatment with estradiol. N Engl J Med 374 (2016), 1221–1231.
29. 29 Lokkegaard, E., Jovanovic, Z., Heitmann, B.L., Kelding, N., Ottesen, B., Pedersen, A.T., The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 53 (2006), 226–233.
30. 30 Carroll, J.S., Meyer, C.A., Song, J., LI, W., Geistlinger, T.R., Eeckhoute, J., et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genet 38 (2006), 1289–1297.
31. 31 Chlebowski, R.T., Anderson, G.L., Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104 (2012), 517–527.
32. 32 Wuest, J.H., Dry, T.J., Edwards, J.E., The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 7 (1953), 801–808.
33. 33 Forte, T.F., (eds.) Hormonal, metabolic, and cellular influences on cardiovascular disease in women. American Heart Association Monograph Series, 1997, Futura Publishing, Armonk, NY.
34. 34 Gerhard, M., Ganz, P., How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 92 (1995), 5–8.
35. 35 Lantto, H., Mikkola, T.S., Tuomikoski, P., Viitasalo, M., Vaananen, H., Sovijarvi, A.R.A., et al. Cardiac repolarization in recently postmenopausal women with or without hot flushes. Menopause 23 (2016), 528–534.
36. 36 Mikkola, T.S., Tuomikoski, P., Lytinen, H., Korhonen, P., Hoti, F., Vattulainen, P., et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocinol Metab 10 (2015), 4588–4594.
37. 37 Allison, M.A., Manson, J.E., Langer, R.D., Carr, J.J., Rossouw, J.E., Pettinger, M.B., et al. Oophorectomy, hormone therapy, subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 15:4Pt 1 (2008), 639–647.
38. 38 Harman, S.M., Black, D.M., Naftolin, F., Brinton, E.A., Budoff, M.J., Cedars, M.I., et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 161 (2014), 249–260.
39. 39 Ingelsson, E., Lundholm, C., Johansson, A.L., Altman, D., Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 32 (2011), 745–750.
40. 40 Atsma, F., Bartelink, M.E.L., Grobbee, D.E., van der Schouw, Y., Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13 (2006), 265–279.
41. 41 Carr, M.C., The emergence of the metabolic syndrome with the menopause. J Clin Endocrinol Metabol 88 (2003), 2404–2411.
42. 42 Pirimoglu, Z.M., Arslan, C., Buyukbayrak, E.E., Kars, B., Karsidag, Y.K., Unal, O., et al. Glucose tolerance of premenopausal women after menopause due to surgical removal of ovaries. Climacteric 14 (2011), 453–457.
43. 43 Appiah, D., Winters, S.J., Homung, C.A., Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care 37 (2014), 725–733.
44. 44 Dorum, A., Tonstad, S., Liavaag, A.H., Michelsen, T.M., Hildrum, D., Dahl, A.A., Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109 (2008), 377–383.
45. 45 Kim, C., Edelstein, S.L., Crandall, J.P., Diabelea, D., Kitabchi, A.E., Hamman, R.F., et al. Diabetes prevention program research group. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause 18 (2011), 857–868.
46. 46 Yoshida, T., Takahashi, K., Yamatani, H., Takata, K., Kurachi, H., Impact of surgical menopause on lipid and bone metabolism. Climacteric 14 (2011), 445–452.
47. 47 Lindsay, R., The menopause: sex steroids and osteoporosis. Clin Obstet Gynecol 30 (1987), 847–859.
48. 48 Mucowski, S.J., Mack, W.J., Shoupe, D., Kono, N., Paulson, R., Hodis, H.N., The effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women. Fertil Steril 101 (2014), 1117–1122.
49. 49 Rocca, W.A., Bower, J.H., Maraganore, D.M., Ahlskog, J.E., Grosshardt, B.R., de Andrade, M., et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69 (2007), 1074–1083.
50. 50 Phung, T.K., Waltoft, B.L., Laursen, T.M., Settnes, A., Kessing, L.V., Mortensen, P.B., et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord 30 (2010), 43–50.
51. 51 Shao, H., Breitner, J.C.S., Whitmer, R.A., Wang, J., Hayden, K., Wengreen, H., et al. Hormone therapy and Alzheimer's Disease. Neurology 79 (2012), 1846–1852.
52. 52 Rocca, W.A., Grosshardt, B.R., Shuster, L.T., Oophorectomy, estrogen, and dementia: a 2104 update. Mol Cell Endocrinol 389 (2014), 7–12.
53. 53 Rocca, W.A., Grosshardt, B.R., Geda, Y.E., Gostout, B.S., Bower, J.H., Maraganore, D.M., et al. Long-term risk of depressive and anxiety symptoms after early oophorectomy. Menopause 15 (2008), 1050–1059.
54. 54 Nathorst-Boos, J., von Schoultz, B., Carlstrom, K., Elective ovarian removal and estrogen replacement therapy- effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 14 (1993), 283–293.
55. 55 Cohen, L.S., Soares, C.N., Vitonis, A.F., Otto, M.W., Harlow, B.L., Risk for new onset depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 63 (2006), 385–390.
56. 56 Soares, C.N., Almeida, O.P., Joffe, H., Cohen, L.S., Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 58 (2001), 529–534.
57. 57 Zweifel, J.E., O'Brien, W.H., A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22 (1997), 189–212.
58. 58 Gibson, C.J., Joffe, H., Bromberger, J.T., Thurston, R.C., Lewis, T.T., Khalil, N., et al. Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among women in midlife. Obstet Gynecol 119 (2012), 935–941.
59. 59 Rivera, C.M., Grosshardt, B.R., Rhodes, D.J., Brown, R.D., Roger, V.L., Melton, L.J. 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16 (2009), 15–23.
60. 60 Parker, W.H., Feskanich, D., Broder, M.S., Chang, E., Shoupe, D., Farquhar, C.M., et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses Health Study. Obstet Gynecol 121 (2013), 709–716.
61. 61 Salpeter, S.R., Cheng, J., Thabane, L., Buckley, N.S., Salpeter, E.E., Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 122 (2009), 1016–1022.
62. 62 Sarrel, P.M., Njike, V.Y., Vinante, V., Katz, D.L., The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59. AJPH 103 (2013), 1583–1588.
63. 63 LaCroix, A.Z., Chlebowski, R.T., Manson, J.E., Aragaki, A.K., Johnson, K.C., Martin, L., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305 (2011), 1305–1314.
64. 64 Schierbeck, L.L., Rejnmark, L., Tofteng, C.L., Stilgren, L., Eiken, P., Mosekilde, L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: a randomized trial. BMJ, 345, 2012, e6409.
65. 65 Marchetti, C., Iadarola, R., Palaia, I., di Donato, V., Perniola, G., Muzil, L., et al. Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause 21 (2014), 763–768.
66. 66 Rebbeck, T.R., Friebel, T., Wagner, T., Lynch, H.T., Garber, J.E., Daly, M.B., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROST Study Group. J Clin Oncol 23 (2005), 7804–7810.
67. 67 Armstrong, K., Schwartz, J.S., Randall, T., Rubin, S.C., Weber, B., Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22 (2004), 1045–1054.
68. 68 O'Brien, K.M., Fei, C., Sandler, D.P., Nichols, H.B., DeRoo, L.A., Weinberg, C.R., Hormone therapy and young-onset breast cancer. Am J Epidemiol 181 (2015), 799–807.
69. 69 Parker, W., Broder, M., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113 (2009), 1027–1037.
70. 70 ACOG Committee on Practice Bulletins. Elective and risk-reducing salpingo-oophorectomy. ACOG Practice Bulletin Number 89. Obstet Gynecol 111 (2008), 231–241.
71. 71 Moorman, P.G., Myers, E.R., Schildkraut, J.M., Iversen, E.S., Wand, F., Warren, N., Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynec 118 (2011), 1271–1279.
72. 72 Trabuco, E.C., Moorman, P.G., Algeciras-Schimnich, A., Weaver, A.L., Cliby, W.A., Association of ovary-sparing hysterectomy with ovarian reserve. Obstet Gynecol 127 (2016), 819–827.
73. 73 Siddle, N., Sarrel, P.M., Whitehead, M.I., The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 47 (1987), 94–100.
74. 74 Sprague, B.L., Trentham-Dietz, A., Cronin, K.A., A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 120 (2012), 595–603.
75. 75 Manson, J.E., Kaunitz, A.M., Menopause management—getting clinical care back on track. N Engl J Med 374 (2016), 803–806.
76. 76 Wierman, M.E., Arlt, W., Basson, R., Davis, S.R., Miller, K.K., Murad, M.H., et al. Androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99 (2014), 3489–3510.